Protective Effects of Ibudilast Against Cisplatin-Induced Hepatotoxicity and Nephrotoxicity Mediated by Prostacyclin Enhancement
Özet
Background and Objective: Cisplatin, a prevalent chemotherapy drug, presents hepatotoxic and nephrotoxic side effects, this study explores ibudilast's potential protective effects against such damage via prostacyclin enhancement. The goal of this research was to assess ibudilast's potential to lessen the negative effects of cisplatin on the hepatic and renal systems. Materials and Methods: The 24 adult female rats were divided into three groups: Control, cisplatin-treated (2.5 mg/kg/day, twice weekly for a month) and cisplatin plus ibudilast-treated (5 mg/kg/day intraperitoneally). Oxidative markers, inflammatory cytokines, ALT, creatinine and tissue prostacyclin levels were assessed, along with histopathological analysis. Results: Substantial increases in ALT, creatinine, MDA, TNF-alpha and IL-6 levels were seen after cisplatin treatment. However, all of these measures showed a substantial decline when ibudilast was added to the cisplatin regimen. After receiving ibudilast medication, the histopathology analysis revealed decreased cisplatin-induced hepatic and renal damage. The cytoprotective function of ibudilast was further supported by elevated tissue prostacyclin levels. Conclusion: Based on our findings, it is suggested that ibudilast has the potential to safeguard against liver and kidney harm induced by cisplatin. It achieves this by not only reducing oxidative stress and inflammation but also by boosting prostacyclin levels, which supports tissue regeneration.
